Celgene believes that its all cash $7.2bn acquisition of Receptos will add at least $4bn to $6bn in peak annual sales to the company's future revenue and help the biotechnology giant exceed a previous goal of $20bn in annual revenue.
Celgene diversifies with $7.2bn Receptos buy
Celgene believes that its all cash $7.2bn acquisition of Receptos will add at least $4bn to $6bn in peak annual sales to the company's future revenue and help the biotechnology giant exceed a previous goal of $20bn in annual revenue.
More from Alimentary/Metabolic
• By
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
• By
The company sees potential for the GLP-1/glucagon receptor dual agonist in MASH as well as alcohol-related liver disease as hopes to move pemvidutide into Phase III in obesity with a partner.
• By
Evaluate Pharma’s top 10 list of unpartnered mid-stage obesity assets shows that few credible challengers to Novo’s Wegovy and Lilly’s Zepbound remain available.
More from Therapy Areas
• By
A decision from the FDA is due by 28 September.
• By
A new “quasi-experimental” study using UK National Health Service data might confirm that GSK’s shingles vaccine helps cut dementia cases.
• By
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.